Methods for treating and diagnosing blinding eye diseases
This invention relates to, in part, methods and compositions that are useful for the diagnosis, treatment, or prevention of a blinding eye disease, including in the discovery of drugs that are efficacious against these diseases. Diseases include, for example, age related macular degeneration and reticular pseudodrusen disease, and the methods described herein include, for example, the method named delayed near infrared analysis (DNIRA).
1. A method for reducing the rate of progression of dry age related macular degeneration (AMD), comprising ophthalmically administering to a subject in need thereof an effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt thereof,
wherein each of R 1 and R 2 is independently H or a C 1 -C 6 alkyl and
R 3 is H or a C 1 -C 6 alkyl.
2. The method of claim 1 , wherein the compound is bindarit.
3. The method of claim 1 , wherein the compound is formulated for ophthalmic administration.
4. The method of claim 1 , wherein the compound is formulated for sustained release.
5. The method of claim 1 , wherein the ophthalmic administration is intravitreal or intraocular administration.
6. The method of claim 1 , wherein the ophthalmic administration is effected to the ocular surface.
7. The method of claim 1 , wherein the dry AMD is early stage AMD.
8. The method of claim 1 , wherein the dry AMD is atrophic dry AMD.
9. The method of claim 1 , wherein the method reduces the rate of progression to late disease.
10. The method of claim 1 , wherein the method reduces the rate of expansion of geographic atropy.
11. The method of claim 1 , wherein the method further comprises administering an additional therapeutic agent.
12. The method of claim 11 , wherein the additional therapeutic agent is one or more of an anti-vascular endothelial growth factor (VEGF) agent, an angiotensin-converting enzyme (ACE) inhibitor, a peroxisome proliferator-activated receptor (PPAR)-gamma agonist, a renin inhibitor, a steroid, and an agent that modulates autophagy.
13. The method of claim 1 , wherein the subject is human.
14. The method of claim 2 , wherein the bindarit is formulated for ophthalmic administration.
15. The method of claim 2 , wherein the bindarit is formulated for sustained release.
16. The method of claim 2 , wherein the ophthalmic administration is intravitreal or intraocular administration.
17. The method of claim 2 , wherein the ophthalmic administration is effected to the ocular surface.